Abstract
Phenotypic manifestations for young children with fragile X syndrome (FXS) include: anxiety, sensory processing challenges, global language and communication deficits and intellectual and developmental disabilities. Many of these symptoms can be treated with medications, including selective serotonin reuptake inhibitors (SSRIs). However to date a clinical trial has not been conducted for children under five years old.
This study investigated the following question: Are there group differences on developmental outcome measures for those children treated with sertraline compared to placebo?
| Original language | American English |
|---|---|
| State | Published - Jul 2014 |
| Externally published | Yes |
| Event | International Fragile X Conference - Anaheim, United States Duration: Jul 16 2014 → Jul 20 2014 Conference number: 14th |
Conference
| Conference | International Fragile X Conference |
|---|---|
| Abbreviated title | NFXF |
| Country/Territory | United States |
| City | Anaheim |
| Period | 7/16/14 → 7/20/14 |
Keywords
- Fragile X Syndrome
- Fragile X
Disciplines
- Occupational Therapy